MRK Biotech Thursday, October 22, 2026 +0.50 Positive

FDA Grants Traditional Approval For Pembrolizumab Or Pembrolizumab And Berahyaluronidase alfa-pmph For Unresectable Or Metastatic TMB-H Solid Tumors With Updated Indication

FDA Grants Traditional Approval For Pembrolizumab Or Pembrolizumab And Berahyaluronidase alfa-pmph For Unresectable Or Metastatic TMB-H Solid Tumors With Updated Indication

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

START FREE — 10,000 calls/day, no key needed